Clinical Trial Update: A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome [Phase 2]

View source ↗

Summary

A multi-center Phase 2 trial evaluating the safety and efficacy of LX1033 in diarrhea-predominant irritable bowel syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome

Drugs mentioned

• LX1033

Snippet

Sponsor: Lexicon Pharmaceuticals | Conditions: Irritable Bowel Syndrome | Phase 2 | Status: COMPLETED